• $113.8M
    Market Cap
  • 14.04%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
0
N/A
0
N/A
N/A
N/A
475,000
+3,858.33%
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
-100.00%
475,000
+265.38%
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-18.1M
+15.12%
-15.7M
-7.21%
-17.0M
+19.75%
-14.2M
+497.85%
Depreciation and Amortization Expense
424,000
+6.00%
400,000
+12.04%
357,000
-6.30%
381,000
+444.29%
Total Operating Expenses
27.6M
+11.67%
24.7M
-8.49%
27.0M
+26.95%
21.2M
+134.37%
Operating Profit
-27.6M
+11.67%
-24.7M
-8.49%
-27.0M
+26.95%
-21.2M
+137.78%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
475,000
+3,858.33%
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
-100.00%
475,000
+3,858.33%
Total Nonoperating Income and Expense
947,000
-20.49%
1.2M
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-27.6M
+11.67%
-24.7M
-8.49%
-27.0M
+26.95%
-21.2M
+137.78%
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-26.6M
+13.30%
-23.5M
-8.44%
-25.7M
+84.69%
-13.9M
+55.69%
Net Income from Continuing Operations Applicable to Common
-26.6M
+13.30%
-23.5M
-8.44%
-25.7M
+84.69%
-13.9M
+55.69%
Basic EPS and Net Income
-0.43
0.00%
-0.43
N/A
N/A
N/A
N/A
N/A
Diluted EPS and Net Income
-0.43
0.00%
-0.43
N/A
N/A
N/A
N/A
N/A
Basic Weighted Average Shares
62.4M
+113,373.75%
54,981
+8.12%
50,853
+32.98%
38,241
-99.88%
Diluted Weighted Average Shares
62.4M
+113,373.75%
54,981
+8.12%
50,853
+32.98%
38,241
-99.88%
Balance Sheet
Cash and Cash Equivalents
16.2M
-11.55%
18.4M
-11.15%
20.7M
-54.18%
45.1M
-35.23%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
16.2M
-11.55%
18.4M
-11.15%
20.7M
-54.18%
45.1M
-35.23%
Total Current Assets
17.9M
-12.44%
20.4M
-11.36%
23.1M
-51.48%
47.5M
-32.59%
Accumulated Depreciation
3.1M
+15.64%
2.6M
+8.15%
2.4M
+1.29%
2.4M
+339.16%
Property and Plant and Equipment and Net
2.9M
+70.05%
1.7M
-2.08%
1.7M
+46.28%
1.2M
+910.26%
Total Long-Term Assets
2.9M
+70.05%
1.7M
+26.53%
1.3M
-2.05%
1.4M
+1,067.52%
Total Assets
39.4M
-5.22%
41.6M
-9.25%
45.8M
-10.43%
51.1M
-27.86%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
249,000
-99.89%
237.0M
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
6.6M
+10.29%
6.0M
+4.60%
5.7M
-16.11%
6.8M
+177.09%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
17.1M
-5.03%
18.0M
-6.98%
19.3M
N/A
N/A
N/A
Total Liabilities
23.7M
-1.20%
24.0M
-4.33%
25.0M
+266.99%
6.8M
+171.36%
Retained Earnings
-148.5M
+21.82%
-121.9M
+23.86%
-98.4M
+35.24%
-72.8M
-77.85%
Total Stockholders Equity
15.7M
-10.68%
17.6M
-15.18%
20.8M
-53.14%
44.3M
-35.19%
Total Shares Outstanding
76.4M
+29.03%
59.2M
+115,976.50%
51,031
-99.90%
50.7M
+128,642.17%
Cash Flow
Cash from Operating Activities
-24.3M
+17.00%
-20.8M
-12.29%
-23.7M
+26.15%
-18.8M
+104.47%
Capital Expenditures
1.2M
+110.97%
556,000
-37.32%
887,000
+162.43%
338,000
+2,314.29%
Cash from Investing Activities
-1.2M
+110.97%
-556,000
-37.32%
-887,000
+162.43%
-338,000
+2,314.29%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
23.3M
+22.15%
19.1M
+14,226.32%
133,000
-99.79%
63.4M
-16.17%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
-4,471.79%
-93.99%
Return on Assets
-65.74%
+22.26%
-53.77%
+1.58%
-52.93%
+132.49%
-22.77%
-3.86%
Return on Equity
-159.62%
+30.39%
-122.42%
+55.26%
-78.85%
+219.81%
-24.65%
-6.46%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
3,858.33%
+3,972.08%
Current Ratio
2.71
-20.61%
3.42
-15.25%
4.03
-42.16%
6.97
-75.67%
Cash Ratio
2.46
-19.81%
3.07
-15.05%
3.61
-45.38%
6.61
-76.62%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow